YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Parker Waichman Alonso LLP Headlines by Topic
Epogen
Study Says Genetic Tests May Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Jun 3, 2008 | Parker Waichman Alonso LLP
Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher...
Congress Investigates Procrit, Epogen and Aranesp Marketing
Apr 2, 2008 | Parker Waichman Alonso LLP
Two members of Congress are looking into to allegations that the marketing of Procrit, Aranesp and Epogen encouraged overuse of the anemia drugs,...
Procrit, Aranesp, Epogen Should Be Allowed for Cancer Patients, With Some Restrictions, FDA Panel Says
Mar 13, 2008 | Parker Waichman Alonso LLP
An advisory panel has weighed in on the safety issues surrounding Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients and...
Procrit, Aranesp, Epogen Could be Restricted by FDA
Mar 12, 2008 | Parker Waichman Alonso LLP
Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug...
Aranesp, Epogen, Procrit Get Another Black Box Warning
Mar 10, 2008 | Parker Waichman Alonso LLP
Aranesp, Epogen and Procrit, drugs used to treat anemia in patients undergoing chemotherapy, will soon bear new black box warnings that they may...
Epogen, Aranesp and Procrit Linked to Potentially Fatal Blood Clots
Feb 27, 2008 | Parker Waichman Alonso LLP
Epogen, Aranesp and Procrit, anemia drugs used to treat cancer patients, have been linked to a higher risk of a potentially fatal type of blood...
Aranesp, Epogen and Procrit Policy Justified, Medicare Official Says.
Feb 11, 2008 | Parker Waichman Alonso LLP
More trouble for Aranesp, Epogen and Procrit. Senior Medicare official Dr. Barry Straube said evidence—including two studies—is...
Procrit, Aranesp and Epogen to See More FDA Scrutiny After Two Studies Show Increased Tumor Growth in Some Cancer Patients Treated with ESAs
Jan 3, 2008 | Parker Waichman Alonso LLP
Two new studies suggest that Procrit, Aranesp and Epogen could carry more risks than first thought, prompting the Food & Drug Administration...
Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients
Dec 11, 2007 | Parker Waichman Alonso LLP
Aranesp, Epogen and Procrit have been linked to yet another deadly side effect. New research suggests that the anemia drugs, known as...
Amgen Warns of More Aranesp Lable Changes
Dec 10, 2007 | Parker Waichman Alonso LLP
Aranesp, an anemia drug often used to treat chemotherapy patients, could soon have safety information on its label updated yet again, the...
Defective Drugs
